Our Pipeline

inMMyCAR is our Phase 1 clinical trial for KLN-1010 and is open and enrolling patients. This first in-human study is designed to assess the safety and preliminary efficacy of a single dose of KLN-1010 in patients with refractory multiple myeloma. Additional information and study site information can be found here and on clinicaltrials.gov (NCT07075185).